Try
TAKEDA PHARMACEUTICAL CO LTD
TAKUnited StatesAlso Japan · 4502.T
92 filed reports · 1,003 financial concepts · 25 earnings calls · 0 media appearances
Filed reports
92 reports · Sep 2016 to Jul 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 366 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Interim · 6-KSEC EDGAR | 45 | 506 | Jan 2019 to Jul 2026 |
| Annual · 20-FSEC EDGAR | 8 | 5,141 | Mar 2019 to Mar 2026 |
| Annual · annual securities reportEDINET | 10 | 3,620 | Mar 2017 to Mar 2026 |
| Q3 · quarterly securities reportEDINET | 8 | 1,395 | Dec 2016 to Dec 2023 |
| Half Year · quarterly securities reportEDINET | 7 | 1,086 | Sep 2016 to Sep 2023 |
| Q1 · quarterly securities reportEDINET | 7 | 1,137 | Jun 2017 to Jun 2023 |
| Q1 · quarterly earnings release (kessan tanshin)EDINET | 3 | 488 | Jun 2024 to Jun 2026 |
| Half Year · half-year securities reportEDINET | 2 | 495 | Sep 2024 to Sep 2025 |
| Q3 · quarterly earnings release (kessan tanshin)EDINET | 2 | 331 | Dec 2024 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q3 | 6-K | Jul 30, 2026 | Jul 30, 2026 | 16 | Open |
| FY2027 Q1 | quarterly earnings release (kessan tanshin) | Jun 30, 2026 | Jul 30, 2026 | 241 | Open |
| FY2026 Q2 | 6-K | Jun 5, 2026 | Jun 5, 2026 | 8 | Open |
| FY2026 | annual securities report | Mar 31, 2026 | Jun 17, 2026 | 734 | Open |
| FY2026 | 20-F | Mar 31, 2026 | Jun 17, 2026 | 1,262 | Open |
| FY2026 Q1 | 6-K | Jan 29, 2026 | Jan 29, 2026 | 8 | Open |
| FY2026 Q3 | quarterly earnings release (kessan tanshin) | Dec 31, 2025 | Jan 29, 2026 | 249 | Open |
| FY2025 Q4 | 6-K | Oct 30, 2025 | Oct 30, 2025 | 10 | Open |
| FY2026 H1 | half-year securities report | Sep 30, 2025 | Oct 30, 2025 | 297 | Open |
| FY2025 Q3 | 6-K | Jul 30, 2025 | Jul 30, 2025 | 34 | Open |
| FY2026 Q1 | quarterly earnings release (kessan tanshin) | Jun 30, 2025 | Jul 30, 2025 | 165 | Open |
| FY2025 | 20-F | Mar 31, 2025 | Jun 25, 2025 | 509 | Open |
Financial data
1,003 concepts · 14,199 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
IFRS312 concepts · 7,057 facts · Sep 2015 to Jun 2026
- EPS (Basic)86 · Sep 2015 to Jun 2026
- Revenue86 · Sep 2015 to Jun 2026
- Profit Attributable to Owners of Parent84 · Sep 2015 to Jun 2026
- Net Income83 · Sep 2015 to Jun 2026
- EPS (Diluted)79 · Sep 2015 to Jun 2026
- Pretax Income79 · Sep 2015 to Jun 2026
- Total Comprehensive Income79 · Sep 2015 to Jun 2026
- Cash and Equivalents74 · Sep 2015 to Jun 2026
- Total Assets73 · Sep 2015 to Jun 2026
- Equity Attributable to Owners of Parent70 · Sep 2015 to Jun 2026
- Financing Cash Flow68 · Sep 2015 to Jun 2026
- Investing Cash Flow68 · Sep 2015 to Jun 2026
- Operating Cash Flow68 · Sep 2015 to Jun 2026
- Ratio of owners' equity to gross assets (IFRS), Key financial data63 · Sep 2015 to Mar 2026
- Stockholders Equity58 · Mar 2017 to Jun 2026
- Bonds and borrowings - CL (IFRS)51 · Mar 2018 to Jun 2026
- Bonds and borrowings - NCL (IFRS)51 · Mar 2018 to Jun 2026
- Capital surplus (IFRS)51 · Mar 2018 to Jun 2026
- Deferred tax assets (IFRS)51 · Mar 2018 to Jun 2026
- Deferred tax liabilities (IFRS)51 · Mar 2018 to Jun 2026
- Goodwill51 · Mar 2018 to Jun 2026
- Income taxes payable - CL (IFRS)51 · Mar 2018 to Jun 2026
- Income taxes receivable - CA (IFRS)51 · Mar 2018 to Jun 2026
- Intangible assets (IFRS)51 · Mar 2018 to Jun 2026
Financial477 concepts · 4,537 facts · Mar 2016 to Mar 2027
- Other62 · Mar 2018 to Mar 2026
- Dividends paid ordinary shares27 · Mar 2016 to Dec 2025
- Dividends paid ordinary shares per share27 · Mar 2016 to Dec 2025
- Trade receivables24 · Mar 2018 to Mar 2026
- Cash and cash equivalents21 · Mar 2016 to Mar 2026
- Equity21 · Mar 2016 to Mar 2026
- Number of outstanding share options21 · Mar 2016 to Mar 2026
- Contingent liabilities recognised in business combination20 · Mar 2017 to Mar 2026
- Current provisions (IFRS)20 · Mar 2017 to Mar 2026
- Deferred tax liability asset20 · Mar 2017 to Mar 2026
- Liabilities arising from financing activities20 · Mar 2017 to Mar 2026
- Noncurrent provisions (IFRS)20 · Mar 2017 to Mar 2026
- Number of shares outstanding20 · Mar 2017 to Mar 2026
- Provisions20 · Mar 2017 to Mar 2026
- Retained earnings20 · Mar 2018 to Mar 2026
- Weighted average exercise price of share options outstanding in sharebased payment arrangement201920 · Mar 2017 to Mar 2026
- Accrued expenses18 · Mar 2018 to Mar 2026
- Accrued labor cost18 · Mar 2018 to Mar 2026
- Assets (IFRS)18 · Mar 2018 to Mar 2026
- Bonds issued18 · Mar 2018 to Mar 2026
- Borrowings18 · Mar 2018 to Mar 2026
- Cash (IFRS)18 · Mar 2018 to Mar 2026
- Contractual commitments for acquisition of intangible assets18 · Mar 2018 to Mar 2026
- Contractual commitments for acquisition of property plant and equipment18 · Mar 2018 to Mar 2026
GAAP177 concepts · 1,479 facts · Mar 2016 to Mar 2026
- Accounts payable - other11 · Mar 2016 to Mar 2026
- Accounts payable - trade11 · Mar 2016 to Mar 2026
- Accounts receivable - trade11 · Mar 2016 to Mar 2026
- Accrued expenses11 · Mar 2016 to Mar 2026
- Asset retirement obligations-NCL11 · Mar 2016 to Mar 2026
- Bonds payable11 · Mar 2016 to Mar 2026
- Buildings and structures, net11 · Mar 2016 to Mar 2026
- Capital surplus11 · Mar 2016 to Mar 2026
- Cash and deposits11 · Mar 2016 to Mar 2026
- Construction in progress11 · Mar 2016 to Mar 2026
- Cost of Revenue11 · Mar 2016 to Mar 2026
- Deferred gains or losses on hedges11 · Mar 2016 to Mar 2026
- Deposits received11 · Mar 2016 to Mar 2026
- Depreciation-SGA11 · Mar 2016 to Mar 2026
- Disposal of treasury shares11 · Mar 2016 to Mar 2026
- Dividend paid per share11 · Mar 2016 to Mar 2026
- Dividends of surplus11 · Mar 2016 to Mar 2026
- EPS (Basic)11 · Mar 2016 to Mar 2026
- EPS (Diluted)11 · Mar 2016 to Mar 2026
- Equity-to-asset ratio, Key financial data11 · Mar 2016 to Mar 2026
- Gross Profit11 · Mar 2016 to Mar 2026
- Income taxes-current11 · Mar 2016 to Mar 2026
- Income taxes - deferred11 · Mar 2016 to Mar 2026
- Income Tax Expense (Benefit)11 · Mar 2016 to Mar 2026
Guidance28 concepts · 506 facts · Jan 2019 to Jul 2026
- Revenue Guidance78 · Jan 2019 to Jul 2026
- Net Income Guidance76 · Jan 2019 to Jul 2026
- Operating Income Guidance76 · Jan 2019 to Jul 2026
- EPS (Diluted) Guidance64 · May 2019 to Jul 2026
- EPS (Diluted) Guidance (Adjusted (non-GAAP))20 · Jul 2019 to Jul 2026
- Operating Income Guidance (Adjusted (non-GAAP))20 · Jul 2019 to Jul 2026
- Revenue Growth Guidance18 · May 2020 to Jul 2026
- Free Cash Flow Guidance14 · Jul 2020 to Feb 2024
- Operating Income Growth Guidance14 · May 2020 to Jul 2025
- Revenue Guidance (Adjusted (non-GAAP))14 · Jul 2022 to Jul 2026
- EPS (Diluted) Growth Guidance12 · May 2021 to Jul 2025
- EPS (Diluted) Growth Guidance (Adjusted (non-GAAP))12 · Aug 2021 to Jul 2025
- Capital Expenditures Guidance10 · Jul 2019 to Jul 2021
- Net Income Growth Guidance10 · Aug 2021 to Jul 2025
- Operating Income Growth Guidance (Adjusted (non-GAAP))10 · Aug 2021 to Jul 2025
- Operating Margin Guidance10 · Feb 2021 to May 2024
- Revenue Growth Guidance (Adjusted (non-GAAP))10 · Oct 2019 to Jul 2025
- Effective Tax Rate Guidance8 · Jul 2020 to Oct 2025
- Capital Expenditures Guidance (cash flow base)6 · Jul 2022 to Feb 2024
- Operating Margin Guidance (Adjusted (non-GAAP))6 · Jul 2019 to Aug 2021
- Revenue Growth Guidance (Adjusted, constant currency)4 · Oct 2019 to Jul 2025
- Capital Expenditures Guidance (Cash basis)2 · Oct 2023
- Effective Tax Rate Guidance (Adjusted (non-GAAP))2 · Feb 2024
- Effective Tax Rate Guidance (on adjusted EBITDA (excluding divestitures); Cash basis)2 · Jul 2022
Product5 concepts · 502 facts · Mar 2017 to Mar 2026
- Revenue495 · Mar 2017 to Mar 2026
- Impairment loss recognised in profit or loss intangible assets other than goodwill4 · Mar 2024 to Mar 2026
- Diabetes1 · Mar 2022
- Entity reorganizations/Divestments1 · Mar 2026
- Shire1 · Mar 2020
Geography3 concepts · 102 facts · Mar 2017 to Mar 2026
- Revenue78 · Mar 2017 to Mar 2026
- Japan14 · Mar 2020 to Mar 2026
- Postemployment benefit expense defined benefit plans10 · Mar 2017 to Mar 2021
Segment1 concepts · 16 facts · Mar 2019 to Mar 2026
- Number of employees16 · Mar 2019 to Mar 2026
Segments
620 factsFigures broken down by business line, region, product or another axis the company reports on.
Products and services82 members · 502 facts
- Alunbrig10 · Mar 2018 to Mar 2026
- Pharmaceutical Products10 · Mar 2017 to Mar 2026
- Royalty And Services10 · Mar 2017 to Mar 2026
- Adcetris9 · Mar 2018 to Mar 2026
- Advate9 · Mar 2018 to Mar 2026
- Albumin9 · Mar 2018 to Mar 2026
- Dexilant9 · Mar 2018 to Mar 2026
- Elaprase9 · Mar 2018 to Mar 2026
- Entyvio9 · Mar 2018 to Mar 2026
- Gastroenterology9 · Mar 2018 to Mar 2026
- Gattex Revestive9 · Mar 2018 to Mar 2026
- Iclusig9 · Mar 2018 to Mar 2026
- Immunoglobulin9 · Mar 2018 to Mar 2026
- Neuroscience9 · Mar 2018 to Mar 2026
- Ninlaro9 · Mar 2018 to Mar 2026
- Oncology9 · Mar 2018 to Mar 2026
- Other Gastroenterology9 · Mar 2018 to Mar 2026
- Other Neuroscience9 · Mar 2018 to Mar 2026
- Other Oncology9 · Mar 2018 to Mar 2026
- Other Product9 · Mar 2018 to Mar 2026
- Other Product Other9 · Mar 2018 to Mar 2026
- Rare Diseases9 · Mar 2018 to Mar 2026
- Replagal9 · Mar 2018 to Mar 2026
- Takhzyro9 · Mar 2018 to Mar 2026
- Trintellix9 · Mar 2018 to Mar 2026
- Adderall XR8 · Mar 2018 to Mar 2026
- Alofisel8 · Mar 2018 to Mar 2024
- Vpriv8 · Mar 2018 to Mar 2025
- Adynovate Adynovi7 · Mar 2020 to Mar 2026
- Azilva F7 · Mar 2018 to Mar 2024
- Feiba7 · Mar 2020 to Mar 2026
- Leuplin Enantone7 · Mar 2020 to Mar 2026
- Other PDT Immunology7 · Mar 2018 to Mar 2024
- Other Rare Hematology7 · Mar 2018 to Mar 2024
- PDT Immunology7 · Mar 2018 to Mar 2024
- Rare Hematology7 · Mar 2018 to Mar 2024
- Velcade7 · Mar 2018 to Mar 2024
- Vyvanse Elvanse7 · Mar 2020 to Mar 2026
- Hemofil Immunate Immunine6 · Mar 2021 to Mar 2026
- Lotriga6 · Mar 2018 to Mar 2023
- Other Rare Diseases6 · Mar 2020 to Mar 2026
- Pantoloc Controloc6 · Mar 2020 to Mar 2025
- Exkivity5 · Mar 2021 to Mar 2024
- Firazyr5 · Mar 2018 to Mar 2022
- Fosrenol5 · Mar 2022 to Mar 2026
- Fruzaqla5 · Mar 2022 to Mar 2026
- Hereditary Angioedema5 · Mar 2018 to Mar 2022
- Rare Metabolic5 · Mar 2018 to Mar 2022
- Recombinate5 · Mar 2020 to Mar 2024
- Takecab F5 · Mar 2018 to Mar 2022
- Vonvendi5 · Mar 2022 to Mar 2026
- Adynovate4 · Mar 2018 to Mar 2021
- Adzynma4 · Mar 2023 to Mar 2026
- Azilva4 · Mar 2023 to Mar 2026
- Eohilia4 · Mar 2023 to Mar 2026
- FEIBA4 · Mar 2018 to Mar 2021
- Leuprorelin4 · Mar 2018 to Mar 2021
- Livtencity4 · Mar 2023 to Mar 2026
- LIVTENCITY4 · Mar 2021 to Mar 2024
- Natpara4 · Mar 2018 to Mar 2021
- Nesina F4 · Mar 2018 to Mar 2021
- Other Hereditary Angioedema4 · Mar 2019 to Mar 2022
- Other PDT4 · Mar 2023 to Mar 2026
- Other Rare Genetics And Other4 · Mar 2021 to Mar 2024
- Other Vaccines4 · Mar 2023 to Mar 2026
- PANTOPRAZOLE4 · Mar 2018 to Mar 2021
- PDT4 · Mar 2023 to Mar 2026
- Qdenga4 · Mar 2023 to Mar 2026
- Rare Genetics And Other4 · Mar 2021 to Mar 2024
- Takecab Vocinti4 · Mar 2023 to Mar 2026
- TAKECABVOCINTI4 · Mar 2021 to Mar 2024
- Vaccines4 · Mar 2023 to Mar 2026
- Vyvanse4 · Mar 2018 to Mar 2021
- Cinryze3 · Mar 2018 to Mar 2020
- Intuniv3 · Mar 2022 to Mar 2024
- Kalbitor3 · Mar 2018 to Mar 2020
- Natpara Natpar3 · Mar 2020 to Mar 2022
- RECOMBINATE3 · Mar 2019 to Mar 2021
- Resolor Motegrity3 · Mar 2024 to Mar 2026
- Diabetes2 · Mar 2022
- Gamma Delta T Cell Therapy Platform And Associated Oncology Programs2 · Mar 2026
- Xiidra1 · Mar 2020
Geographical areas12 members · 102 facts
- Country Of Domicile12 · Mar 2017 to Mar 2026
- Foreign Countries12 · Mar 2017 to Mar 2026
- Europe And Canada10 · Mar 2017 to Mar 2026
- JP10 · Mar 2017 to Mar 2026
- Latin America10 · Mar 2017 to Mar 2026
- Other Countries Not Separately Reported10 · Mar 2017 to Mar 2026
- Russian Federation And Commonwealth Of Independent States10 · Mar 2017 to Mar 2026
- US10 · Mar 2017 to Mar 2026
- Asia5 · Mar 2017 to Mar 2021
- Asia Excluding Japan5 · Mar 2020 to Mar 2024
- Asia Excluding Japan And China4 · Mar 2023 to Mar 2026
- CN4 · Mar 2023 to Mar 2026
Operating segments1 member · 16 facts
- PharmaceuticalBusinessReportableSegmentMember16 · Mar 2019 to Mar 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
25 calls · Jul 2018 to Jul 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2027 Q1Jul 30, 2026
- FY2026 Q4May 13, 2026
- FY2025 Q4May 13, 2026
- FY2026 Q3Jan 29, 2026
- FY2025 Q3Jan 29, 2026
- FY2025 Q2Oct 31, 2025
- FY2025 Q1Jul 30, 2025
- FY2024 Q4May 9, 2025
- FY2024 Q3Jan 30, 2025
- FY2024 Q2Oct 31, 2024
- FY2024 Q1Aug 2, 2024
- FY2023 Q4May 9, 2024
- FY2023 Q3Feb 1, 2024
- FY2023 Q2Oct 26, 2023
- FY2023 Q1Jul 27, 2023
- FY2022 Q4May 11, 2023
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.